Shen Meixiao, Hu Pingping, Donskov Frede, Wang Guanghui, Liu Qi, Du Jiajun
Institute of Oncology, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, P. R. China.
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
PLoS One. 2014 Jun 6;9(6):e98259. doi: 10.1371/journal.pone.0098259. eCollection 2014.
Tumor-associated neutrophils (TAN) have been reported in a variety of malignancies. We conducted an up-to-date meta-analysis to evaluate the prognostic role of TAN in cancer.
Pubmed, Embase and web of science databases were searched for studies published up to April 2013. Pooled hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were calculated. The impact of neutrophils localization and primary antibody were also assessed.
A total of 3946 patients with various solid tumors from 20 studies were included. High density of intratumoral neutrophils were independently associated with unfavorable survival; the pooled HRs were 1.68 (95%CI: 1.36-2.07, I2 = 55.8%, p<0.001) for recurrence-free survival (RFS)/disease-free survival (DFS), 3.36 (95%CI: 2.08-5.42, I2 = 0%, p<0.001) for cancer-specific survival (CSS) and 1.66 (95%CI: 1.37-2.01, I2 = 70.5%, p<0.001) for overall survival (OS). Peritumoral and stromal neutrophils were not statistically significantly associated with survival. When grouped by primary antibody, the pooled HRs were 1.80 (95%CI: 1.47-2.22, I2 = 67.7%, p<0.001) for CD66b, and 1.44 (95%CI: 0.90-2.30, I2 = 45.9%, p = 0.125) for CD15, suggesting that CD66b positive TAN might have a better prognostic value than CD15.
High levels of intratumoral neutrophils are associated with unfavorable recurrence-free, cancer-specific and overall survival.
肿瘤相关中性粒细胞（TAN）已在多种恶性肿瘤中被报道。我们进行了一项最新的荟萃分析，以评估TAN在癌症中的预后作用。
检索了截至2013年4月发表在PubMed、Embase和科学网数据库上的研究。计算合并风险比（HRs）及其相应的95%置信区间（CIs）。还评估了中性粒细胞定位和一抗的影响。
共纳入来自20项研究的3946例患有各种实体瘤的患者。肿瘤内中性粒细胞高密度与不良生存独立相关；无复发生存期（RFS）/无病生存期（DFS）的合并HR为1.68（95%CI：1.36 - 2.07，I2 = 55.8%，p < 0.001），癌症特异性生存期（CSS）为3.36（95%CI：2.08 - 5.42，I2 = 0%，p < 0.001），总生存期（OS）为1.66（95%CI：1.37 - 2.01，I2 = 70.5%，p < 0.001）。肿瘤周围和基质中的中性粒细胞与生存无统计学显著相关性。按一抗分组时，CD66b的合并HR为1.80（95%CI：1.47 - 2.22，I2 = 67.7%，p < 0.001），CD15的合并HR为1.44（95%CI：0.90 - 2.30，I2 = 45.9%，p = 0.125），表明CD66b阳性TAN可能比CD15具有更好的预后价值。
肿瘤内高水平的中性粒细胞与不良的无复发生存期、癌症特异性生存期和总生存期相关。
